NETRIS Pharma is a biotechnology company developing pioneer targeted therapies for the treatment of cancer.

Its research is based on the innovative concept of Dependence Receptors.

NETRIS Pharma develops innovative anti-cancer drugs

NETRIS Pharma has a first candidate in the late stages of preclinical development, which targets the Netrin-1 ligand

Five other programs are in preclinical research stage

1
1

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group.

Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

Our news
ANR

6th July 2016: ANR granted the TROY program aiming at targeting Dependence Receptors in oncology and hematology, with NETRIS Pharma as the industrial partner

| News | No Comments

NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at…

2014_logo_MENESR_horizontal_web

31st March, 2016: Agnes Bernet – Co-founder and CSO of NETRIS Pharma – is nominated as “Chevalier de la Légion d’Honneur”

| News | No Comments

NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – was nominated as “Chevalier de la Légion d’Honneur”, following the recommendation of Najat Vallaud-Belkacem, French Minister…

Prix IJC 2015

5th January, 2016: Agnes Bernet – Co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award

| News | No Comments

NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award from the French Minister of Education and Research and the…

beebanner_sm

19th-20th May, 2015: Stephane Depil – CEO of NETRIS Pharma – will attend the BioEquity Europe 2015 meeting in Vienna, Austria

| Event | No Comments

NETRIS Pharma will attend the BioEquity Europe 2015 meeting in Vienna, Austria (May 19th-20th). During the “Next Wave Companies” session, Stéphane Depil – CEO – will present NETRIS Pharma activities…

AM15_Logo

18th-22nd April, 2015: NETRIS Pharma will present recent data about NP137 preclinical development at the AACR Annual Meeting 2015 in Philadelphia, US

| Event | No Comments

NETRIS Pharma will attend the AACR Annual Meeting 2015 in Philadelphia, US (April 18th-22nd). For this occasion, NETRIS Pharma will present recent data regarding its first-in-class humanized anti-Netrin-1 antibody NP137,…

26th-EORTC-NCI-AACR

18th-21st November, 2014: NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain

| Event | No Comments
NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. For this occasion, NETRIS Pharma will present the preclinical characteristics of NP137, its...
logo_Site_retina-01

NETRIS Pharma presents its new website

| News | No Comments
NETRIS Pharma - a Lyon-based biotech firm aiming at translating the dependence receptor paradigm to the clinic - presents today its new website. This website introduces company missions, objectives, business...